Financial Contrast: Evofem Biosciences (NASDAQ:EVFM) and BetterLife Pharma (OTCMKTS:PVOTF)

Earnings and Valuation

This table compares BetterLife Pharma and Evofem Biosciences”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BetterLife Pharma	N/A	N/A	-$14.78 million	N/A	N/A
Evofem Biosciences	$11.39 million	0.12	$52.98 million	($0.06)	-0.18

Evofem Biosciences has higher revenue and earnings than BetterLife Pharma.

Institutional & Insider Ownership

0.2% of Evofem Biosciences shares are held by institutional investors. 34.8% of BetterLife Pharma shares are held by company insiders. Comparatively, 0.0% of Evofem Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares BetterLife Pharma and Evofem Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BetterLife Pharma	N/A	-205.15%	-147.23%
Evofem Biosciences	-46.42%	-91.97%	-61.93%

Summary

Evofem Biosciences beats BetterLife Pharma on 6 of the 8 factors compared between the two stocks.

About BetterLife Pharma

BetterLife Pharma, Inc. is an early stage pharmaceutical company, which engages in the development and commercialization of therapeutic pharmaceutical and nutraceutical products. It also offers drug delivery platform technologies. Its product lines include capsules, tablets, and softgels; bulk powder; stick packs; beverages; oral solutions; lotions, creams, and gels; pet food additives; gum, mints, and candies; and sexual health products. It distributes its product under the Pivot Naturals brand. The company was founded on June 10, 2002 and is headquartered in Vancouver, Canada.

About Evofem Biosciences

Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.